Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia
T Papaluca, J O'Keefe, S Bowden, JS Doyle, M Stoove, M Hellard, AJ Thompson
Journal of Clinical Virology | ELSEVIER | Published : 2019
BACKGROUND: Direct-acting antivirals (DAA) have revolutionised hepatitis C virus (HCV) treatment, and most regimens include an NS5A inhibitor. Certain amino-acid substitutions confer resistance to NS5A inhibitors, termed resistance-associated substitutions (RAS). If present at baseline, they can reduce virological response rates. Population-based sequencing (PBS) is generally used for baseline sequencing, however next generation sequencing (NGS) reduces the threshold for detection of sequences encoding RAS from 20% to 5%. We determined the prevalence of NS5A RAS at baseline amongst Australian chronically infected with genotype (GT)1a, GT1b and GT3 HCV, using both PBS and NGS. METHODS: Sample..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council of Australia
TP received funding from an Australian Government Research Training Program Scholarship and the Department of Gastroenterology, St. Vincent's Hospital Melbourne, Australia; AJT and MH received funding from the National Health and Medical Research Council of Australia (Practitioner Fellowships 1142976 and 1112297, respectively). This work was supported by National Health and Medical Research Council of Australia Partnership grant 1116161 and program grants 1132902 and 1066537.